ClinicalTrials.gg
RecruitingNCT07864025ILUMINAUpdated Oct 7, 2026

Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel Photon-counting CT in Stable Angina

An observational study in Coronary Artery Disease (CAD), Stable Angina Pectoris and Ischaemic Heart Disease (IHD), sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Queen Mary University of London · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Coronary Artery Disease with a site in United Kingdom — 43 open to participants now, 73 under way, 6 of them phase 3. Coronary Artery Disease · United Kingdom.

Planned enrollment
74th of 93
70 · median 320
Started
2026
with 13 others
Observational
93 of 283
18 open now
Primary completion
2029-04
later than 60 of 72 live
Registered
282nd of 283
by date
Lead sponsor
7 of 283
Queen Mary University of London

Among the 283 studies in Coronary Artery Disease with a site in United Kingdom, this one is the 74th largest by planned enrollment of the 93 observational ones that give a count, is one of 14 that started in 2026, is one of 93 observational ones, reaches primary completion later than 60 of the 72 other live ones, and was the 282nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

43 of the 283 studies in Coronary Artery Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Coronary Artery Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic disease. If we could identify these vulnerable patients, then in wider clinical practice in the future we might be able to treat them better with new therapies that can otherwise be expensive or come with a risk of side-effects. Traditionally, the assessment of atherosclerotic disease and the identification of the plaques that will cause heart attacks is performed using invasive imaging - imaging taken by passing a wire into the arteries of the heart that has a camera on its tip. Invasive imaging, however, can be used only in patients with symptoms and has risks. Photon counting (PC) CT is a new CT system that has image quality comparable to invasive imaging and can be used in the community to examine individuals with stable angina symptoms. In this study we aim to compare how well PC-CT detects high-risk plaques compared with invasive imaging and in due course develop a platform that will expedite the analysis of CT images to allow its broad use in the clinical practice.

03

Conditions studied

  • Coronary Artery Disease (CAD)
  • Stable Angina Pectoris
  • Ischaemic Heart Disease (IHD)

Keywords

  • Photon-counting CT
  • Coronary plaque characterization
  • Lipid-rich plaque
  • Intravascular ultrasound
  • Near-infrared spectroscopy
  • Vulnerable plaque
  • Coronary Artery Disease (CAD)
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a chronic coronary syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give
  • Between ages 18-79
  • Patients with a stable coronary syndrome that had recent PC-CTA showing at least one lesion requiring further evaluation with intravascular imaging or fractional flow reserve and is considered suitable for PCI under IVUS guidance

Exclusion criteria

Exclusion Criteria:

  • Unable to or unwilling to give
  • Age >80 years
  • Recent acute coronary syndrome within \< 3 months
  • Renal failure ( \<60ml/min/1.73m²)
  • History of previous coronary artery bypass surgery
  • Decompensated heart failure, or ≤30%
  • Previous heart transplantation
  • Intravenous contrast allergy
  • Unable to receive treatment with aspirin, heparin, or thienopyridines
  • Anticipated \<1 year
  • Pregnancy
  • Patient that requires surgical revascularisation
  • Extensive coronary artery disease (i.e. multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with NIRS-IVUS imaging
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Chronic Coronary Syndrome

    Other: observational study

Interventions

  • Otherobservational study

    Observation study comparing Photon-counting CT with intravascular coronary imaging in patients with chronic coronary syndrome

06

What researchers measure

Primary outcomes

  1. Compare the efficacy of PC-CTA and of conventional CTA in assessing the percent atheroma volume (PAV) using the output of the NIRS-IVUS analysis as the reference standard

    Time frame: After each patient has had coronary angiography

Secondary outcomes

  1. Identify the optimal reconstruction method of PC-CTA data for measuring the PAV in the studied segment using the NIRS-IVUS estimations as the reference standard.

    Time frame: After each patient has had coronary angiography.

  2. Compare the accuracy of PC-CTA and conventional CTA in measuring flow patterns.

    Time frame: After each patient has had coronary angiography.

07

Study locations

1 of 1 sites recruiting
  • William Harvey Research Institute, Barts and The London, Queen Mary University of London
    London, United Kingdom
    Recruiting
08

References and documents

Publications

  • Sakai K, Shin D, Singh M, Malik S, Dakroub A, Sami Z, Weber J, Cao JJ, Parikh R, Chen L, Sosa F, Cohen DJ, Moses JW, Shlofmitz RA, Collet C, Shlofmitz E, Jeremias A, Khalique OK, Ali ZA. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025 Feb 4;85(4):339-348. doi: 10.1016/j.jacc.2024.10.069. Epub 2024 Oct 28. PubMed 39466216 ↗
  • Ramasamy A, Hamid A Khan A, Cooper J, Simon J, Maurovich-Horvat P, Bajaj R, Kitslaar P, Amersey R, Jain A, Deaner A, Reiber JH, Moon JC, Dijkstra J, Serruys PW, Mathur A, Baumbach A, Torii R, Pugliese F, Bourantas CV. Implications of computed tomography reconstruction algorithms on coronary atheroma quantification: Comparison with intravascular ultrasound. J Cardiovasc Comput Tomogr. 2023 Jan-Feb;17(1):43-51. doi: 10.1016/j.jcct.2022.09.004. Epub 2022 Sep 21. PubMed 36270952 ↗
  • Ramasamy A, Parasa R, Sokooti H, Zhang X, Tanboga IH, Kitslaar P, Broersen A, Rathod KS, Amersey R, Jain A, Ozkor M, Reiber JHC, Dijkstra J, Serruys PW, Moon JC, Mathur A, Torii R, Pugliese F, Baumbach A, Bourantas CV. Computed tomography versus near-infrared spectroscopy for the assessment of coronary atherosclerosis. EuroIntervention. 2024 Dec 2;20(23):e1465-e1475. doi: 10.4244/EIJ-D-24-00096. PubMed 39618266 ↗
  • Ramasamy A, Pugliese F, Tanboga IH, Kitslaar P, Dijkstra J, Mathur A, Torii R, Moon JC, Baumbach A, Bourantas CV. Head-to-Head Comparison of Near-Infrared Spectroscopy-Intravascular Ultrasound and Coronary Computed Tomography Angiography in Assessing Atheroma Characteristics. JACC Cardiovasc Imaging. 2024 Dec;17(12):1507-1510. doi: 10.1016/j.jcmg.2024.07.005. Epub 2024 Sep 11. No abstract available. PubMed 39269412 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Apr 2029, 31 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 31 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 7, 2026
StartActual
Aug 19, 2026
Primary completionEst.
Apr 3, 2029
CompletionEst.
Apr 3, 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864025
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Aug 19, 2026
Primary completion
Apr 3, 2029 (estimated)
Completion
Apr 3, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Ameer Hamid A Khan, MBBS BSc MSc
Contact
a.h.a.khan@qmul.ac.uk
447780356028
Christos V Bourantas, MD PhD
Contact
cbourantas@gmail.com
Christos V Bourantas, MD PhD
principal investigator · Barts Health NHS Trust and Queen Mary University of London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion